The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 President’s Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
    • Media
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 President’s Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
    • Media
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
    • Media
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
      • Summit Sponsors
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Master Class 5.0 Trial Academy 2021
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

$97M Settlement Between Gilead and DOJ Over Kickbacks

Posted on September 25, 2020 by The National Trial Lawyers

Amid an industrywide kickbacks investigation into pharma’s charity contributions, Gilead Sciences has become the latest drugmaker to strike a deal. Though the company says it doesn’t believe it violated any laws, it agreed to pay $97 million to resolve kickbacks allegations.

Gilead inked the settlement with the Department of Justice (DOJ) to resolve claims it used a patient foundation as a “conduit” to cover Medicare patients’ copays for Letairis, a pulmonary arterial hypertension drug that’s now off patent.

Gilead is the latest drugmaker to strike a deal in the yearslong probe, following settlements of various sizes for Sanofi, Pfizer, Astellas, Amgen, Alexion and United Therapeutics, among others. 

Read the source article at Pharma News

Posted in Civil Plaintiff

Comments are closed.

Recent Posts

What Are the Symptoms of a Traumatic Brain Injury, and Should You Contact an Attorney?

What Are the Symptoms of a Traumatic Brain Injury, and Should You Contact an Attorney?

July 27th, 2021

Traumatic brain injury may be defined as any type of trauma that has an effect on how the brain functions. As we know, t[Read More...]
First-ever Civil Rights Criminal Justice Legal Summit

First-ever Civil Rights Criminal Justice Legal Summit

July 26th, 2021

On September 22 - 24, 2021, The Cochran Firm will present the first-ever Civil Rights Criminal Justice Legal Summit, hos[Read More...]
Arkansas Will Receive $216 Million of a $26 Billion Opioid Settlement

Arkansas Will Receive $216 Million of a $26 Billion Opioid Settlement

July 26th, 2021

rkansas Attorney General Leslie Rutledge announced Friday (July 23) a $26 billion agreement with pharmaceutical manufacturers[Read More...]
Sutter Health Closes in on a $575 Million Settlement in an Antitrust Case

Sutter Health Closes in on a $575 Million Settlement in an Antitrust Case

July 26th, 2021

More than 18 months after Sutter Health agreed to a tentative settlement in a closely watched antitrust case joined by the Ca[Read More...]
UPMC Settles Data Breach Allegations for $2.65 Million

UPMC Settles Data Breach Allegations for $2.65 Million

July 23rd, 2021

UPMC has reached a financial settlement with thousands of employees whose personal information was hacked in 2014 and used to[Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.